Access Pharmaceuticals
Affiliate(s):
The School of Pharmacy, University of London
Jiangsu Aosaikang Pharmaceutical
Dong-A Pharmaceuticals

Current as of: June 22, 2010  

Brand Name: ProLindac
Other Designation: AP5346  

AP5346 is a soluble, synthetic, platinum-polymer complex with a mean molecular weight of 20 kD, designed to deliver high concentrations of diaminocyclohexane (DACH) platinum directly to solid tumors; oxaliplatin prodrug.  

Phase I (begin 4/03, completed 4/05) Europe (France, Netherlands), USA - solid tumors, advanced, refractory
Phase II (begin 6/06, ongoing 11/07) Europe - ovarian cancer, recurrent
Phase I/II (ongoing 12/05) USA (combination) - colorectal cancer
Phase II (begin 5/06, closed 12/07) USA - head and neck cancer, inoperable, recurrent
 

AEterna Zentaris
Affiliate(s):
Keryx Biopharmaceuticals

Current as of: April 16, 2010  

Generic Name: Perifosine
Other Designation: KRX-0401, D-21266  

Perifosine, a novel heterocyclic alkylphospholipid (alkylphosphocholine derivative) analog of hexadecylphosphocholine (miltefosine), is an oral Akt inhibitor that activates the MAP kinase (MEK/ERK) pathway leading to the activation of p21 independently of p53.

Administration Route: PO  

Phase I (begin 7/96, ongoing 5/99) Europe (Germany), phase I (begin 2/99, completed 5/04) USA, phase I (begin 2/00, completed 12/03) USA, phase I (completed 6/04) Europe (Netherlands) (combination), phase I (begin 11/04, closed 12/06) USA (combination), phase I (begin 8/04, completed 1/07) USA (combination), phase I (begin 10/06, closed 3/08, completed 3/10) USA, phase I (ongoing 6/06) USA (combination), phase I (begin 8/04, completed 12/06) USA (combination), phase I (begin 11/04, closed 4/08) USA (combination); phase IIa (begin 1/05, closed 3/08, terminated 2/09) USA; phase II (begin 8/05, closed 4/08) USA - solid tumors, advanced or metastatic, refractory
Phase II (begin 7/03, completed 9/05) USA, phase II (begin 8/03, suspended 4/04, completed 7/06) Canada - pancreatic cancer, locally advanced or metastatic
Phase II (begin 3/03, closed 4/07, completed 2/09) USA, phase II (begin 4/03, completed 3/05) USA - prostate cancer, hormone-sensitive, biochemically recurrent • prostate cancer, metastatic, androgen-independent
Phase II (begin 6/03, completed 5/07) Canada, phase II (begin 5/05, ongoing 1/06) USA (combination) - breast cancer, locally advanced or metastatic, recurrent or refractory, Er or Pr positive
Phase II (begin 6/03, closed 3/04) USA, phase II (begin 6/03, suspended 4/04, completed 3/06) Canada; phase II (begin 12/06, closed 12/08) - sarcoma, soft tissue, locally advanced or metastatic
Phase II (begin 6/03, completed 12/05) Canada - melanoma, metastatic or recurrent, first line
Phase II (begin 5/03, closed 7/04, completed 4/09) USA - head and neck cancer, metastatic or recurrent
Phase I/II (begin 9/04, terminated 2/09) USA; phase II (begin 9/05, closed 11/07) (multimodality) Europe (Netherlands) - non-small cell lung cancer (nsclc), refractory
Phase I/II (begin 8/06, closed 12/08) USA (combination); phase II (begin 1/06, closed 10/07) USA (combination), phase II (begin 9/06, closed 12/07) USA; phase I (begin 12/06, closed 12/08) USA (combination); phase III (begin 12/09, ongoing 4/10) USA - multiple myeloma, relapsed or refractory • Waldenstrom's macroglobulinemia, relapsed or refractory
Phase II (begin 5/08, ongoing 2/09) USA - solid tumors • multiple myeloma
Phase II (begin 5/06, closed 2/09) USA - glioma, malignant, recurrent or progressive • glioblastoma multiforme (GBM), recurrent
Phase II (begin 3/05, closed 5/06) USA - hepatocellular carcinoma (HCC), advanced
Phase I (begin 10/06, closed 12/08) USA (combination), phase I (begin 10/06, closed 4/08, completed 3/10) USA (combination); phase II (begin 3/07, closed 2/09) USA; phase II (begin 1/05, terminated 2/09) USA; phase II (begin 7/07, closed 6/09) USA, phase II (begin 08/06, closed 12/08) USA (combination) - renal cell carcinoma (RCC), metastatic, refractory, second or third line • gastrointestinal stromal tumors (GIST), advanced
Phase I (begin 2/07, closed 6/09) USA - ovarian cancer, relapsed
Phase I (begin 3/06, ongoing 7/09) USA (combination); phase II (begin 10/06, completed 12/08) USA - leukemia, refractory or relapsed • chronic myelogenous leukemia (CML)
Phase II (begin 8/05, closed 4/08, ongoing 2/09) USA (combination); phase I (begin 9/09, closed 1/10) USA; phase III (begin 4/10) USA - colorectal cancer, metastatic, refractory, second or third line